{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T02:22:07Z","timestamp":1785378127078,"version":"3.55.0"},"reference-count":28,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>We conducted a one-year prospective study involving the enrollment of 58 patients with Hidradenitis Suppurativa. Through a retrospective analysis of data on the same patients, with reference to the year prior to the initiation of the anti-TNF\u03b1 drug adalimumab, we aimed to show how the advent of this biologic therapy changes the number of days of antibiotic therapy, the number of flare-ups per year, and their duration in days, as well as the quality of life and perceived pain of patients.<\/jats:p>","DOI":"10.3390\/jcm12030837","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T04:19:22Z","timestamp":1674447562000},"page":"837","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["How Adalimumab Impacts Antibiotic Prescriptions in Patients Affected by Hidradenitis Suppurativa: A 1-Year Prospective Study and Retrospective Analysis"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2523-050X","authenticated-orcid":false,"given":"Fabrizio","family":"Martora","sequence":"first","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80138 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8401-5730","authenticated-orcid":false,"given":"Claudio","family":"Marasca","sequence":"additional","affiliation":[{"name":"Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione \u201cG. Pascale\u201d, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8137-8392","authenticated-orcid":false,"given":"Vincenzo","family":"Picone","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80138 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Fornaro","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80138 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1803-2046","authenticated-orcid":false,"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80138 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Fabbrocini","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80138 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1468-3083.2009.03356.x","article-title":"Hidradenitis suppurativa","volume":"23","author":"Revuz","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/jid.2012.255","article-title":"Incidence of hidradenitis suppurativa and associated factors: A population-based study of Olmsted County, Minnesota","volume":"133","author":"Vazquez","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/CCID.S111019","article-title":"Hidradenitis suppurativa: From pathogenesis to diagnosis and treatment","volume":"10","author":"Napolitano","year":"2017","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1684\/ejd.2018.3254","article-title":"The Hidradenitis Suppurativa (HS) \u201cMultidisciplinary Unit\u201d: A rationale and practical proposal for an organised clinical approach","volume":"28","author":"Chiricozzi","year":"2018","journal-title":"Eur. J. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000521712","article-title":"A Case of Pemphigus Vulgaris and Hidradenitis Suppurativa: May Systemic Steroids Be Considered in the Standard Management of Hidradenitis Suppurativa?","volume":"8","author":"Martora","year":"2022","journal-title":"Ski. Appendage Disord."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1001\/jama.2017.16691","article-title":"Hidradenitis Suppurativa: Advances in Diagnosis and Treatment","volume":"318","author":"Saunte","year":"2017","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaad.2008.11.911","article-title":"Hidradenitis suppurativa: A comprehensive review","volume":"60","author":"Alikhan","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","first-page":"830","article-title":"Color Doppler as a tool for correlating vascularization and pain in hidradenitis suppurativa lesions","volume":"25","author":"Nazzaro","year":"2019","journal-title":"Ski. Res. Technol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/bjd.19343","article-title":"Doppler ultrasound-based noninvasive biomarkers in hidradenitis suppurativa: Evaluation of analytical and clinical validity","volume":"184","author":"Grand","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/ced.14127","article-title":"Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab","volume":"45","author":"Cannizzaro","year":"2020","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1002\/acr.20543","article-title":"Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP)","volume":"63","author":"Hawker","year":"2011","journal-title":"Arthritis Care Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.3889\/oamjms.2018.358","article-title":"A Dermatological Questionnaire for General Practitioners with a Focus on Hidradenitis Suppurativa","volume":"6","author":"Marasca","year":"2018","journal-title":"Open Access Maced. J. Med. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e2022099","DOI":"10.5826\/dpc.1202a99","article-title":"Adalimumab Effect on Pain in Hidradenitis Suppurativa Patients: Systematic Review and Meta-Analysis","volume":"12","author":"Tsentemeidou","year":"2022","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jdcr.2022.03.008","article-title":"Hidradenitis suppurativa flares following COVID-19 vaccination: A case series","volume":"23","author":"Martora","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ruggiero, A., Martora, F., Picone, V., Marano, L., Fabbrocini, G., and Marasca, C. (2022). Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020455"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/ced.14512","article-title":"Long-term antibiotic use for the treatment of hidradenitis suppurativa consistent with guideline recommendations","volume":"46","author":"Kitts","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/ced.15291","article-title":"Strategies adopted in a southern Italian referral centre to reduce adalimumab discontinuation: Comment on \u2018Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?\u2019","volume":"47","author":"Martora","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1111\/jdv.17151","article-title":"Corticosteroid rescue therapy in relapsing hidradenitis suppurativa treated with adalimumab","volume":"35","author":"Arenbergerova","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jdv.15826","article-title":"Hidradenitis suppurativa epidemiology: From the first Italian registry in 2009 to the most recent epidemiology updates\u2014Italian Registry Hidradenitis Suppurativa project 2","volume":"33","author":"Bettoli","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1111\/ced.15306","article-title":"Management of patients with hidradenitis suppurativa during COVID-19 vaccination: An experience from southern Italy. Comment on: \u2018Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa\u2019","volume":"47","author":"Martora","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2340\/00015555-3520","article-title":"Clinical and Ultrasonographic Profile of Adalimumab-treated Hidradenitis Suppurativa Patients: A Real-life Monocentric Experience","volume":"100","author":"Chiricozzi","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Napolitano, M., Fabbrocini, G., Martora, F., Picone, V., Morelli, P., and Patruno, C. (2021). Role of Aryl Hydrocarbon Receptor Activation in Inflammatory Chronic Skin Diseases. Cells, 10.","DOI":"10.3390\/cells10123559"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1111\/jdv.17178","article-title":"Effectiveness of Secukinumab in the treatment of moderate-severe hidradenitis suppurativa: Results from an Italian multicentric retrospective study in a real-life setting","volume":"35","author":"Ribero","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/exd.14338","article-title":"Target molecules for future hidradenitis suppurativa treatment","volume":"30","author":"Zouboulis","year":"2021","journal-title":"Exp. Dermatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/3\/837\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:11:39Z","timestamp":1760119899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/3\/837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["jcm12030837"],"URL":"https:\/\/doi.org\/10.3390\/jcm12030837","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]}}}